Jean-Luc Perrot
Prof Jean-Luc Perrot is an expert in Dermatology at Centre Hospitalier Universitaire de Saint-Etienne (France). As of October 2026, ScienceLeadR ranks Jean-Luc Perrot in the top 1% of experts worldwide for Pigmentation Disorders, Keratosis and Skin Neoplasms. Jean-Luc Perrot has authored 671 publications, the most recent in 2026, and is an investigator in 34 clinical trials, 13 of them ongoing. SLR score: 2,601 (community average: 125). How the SLR is computed.
LeadR Profile
Dermatology
Subspecialties: Oncology - Medical Imaging - Ophthalmology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1989 - 2026
Number : 671
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Efficacy and safety of subcutaneous efgartigimod with prednisone in moderate-to-severe pemphigus (ADDRESS): a global, phase III, randomised controlled, double-blind trial. PMID 42723554 — syphilis, safety, prednisone, adrenal cortex hormones, desmogleins, therapeutics, pemphigus, dermatology | Br J Dermatol | 2026 | 0 |
| The spectrum of eosinophilic cellulitis (Wells' syndrome): new insights based on 114 cases. PMID 42551694 — hypersensitivity, adrenal cortex hormones, cellulitis, eosinophils, therapeutics | J Allergy Clin Immunol Pract | 2026 | 0 |
| Line-Field Confocal Optical Coherence Tomography (LC-OCT) of Spitz Naevi: Preliminary Observations According to Dermoscopic Patterns. PMID 42543718 — tomography, tomography, optical coherence, dermatology, dermoscopy | Int J Dermatol | 2026 | 0 |
| Added value of LC-OCT in equivocal melanocytic lesions: A prospective study. PMID 42518185 — sexually transmitted diseases, triage, melanoma, predictive value of tests, skin diseases, wounds and injuries, prospective studies, dermoscopy | J Eur Acad Dermatol Venereol | 2026 | 0 |
| Preclinical Safety and Feasibility Study of Line-Field Confocal Optical Coherence Tomography for Ophthalmology Applications. PMID 42383819 — feasibility studies, safety, ophthalmology, tomography, cornea, tomography, optical coherence, eye diseases, retinaldehyde | Transl Vis Sci Technol | 2026 | 0 |
Clinical Studies 34
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 2
Ongoing Clinical Trials
13 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A study to evaluate the long term safety tolerability and efficacy of subcutaneous sonelokimab in participants with moderate to severe hidradenitis suppurativa 2025-520564-17-00 — safety, hidradenitis suppurativa, hidradenitis | Phase 3 | Active not recruiting | 2025 |
| Brivekimig for the treatment of moderate to severe hidradenitis suppurativa 2025-522333-61-00 — hidradenitis suppurativa, maintenance, hidradenitis, therapeutics | Phase 2 | Not yet recruiting | 2026 |
| Hidradenitis Suppurativa Evaluation of lutikizumab in Adult and Adolescent Subjects 2024-510730-40-00 — safety, hidradenitis suppurativa, signs and symptoms, hidradenitis, adolescent | Phase 3 | Active not recruiting | 2024 |
| Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate to Severe Atopic Dermatitis 2023-508235-31-00 — safety, dermatitis, signs and symptoms, adolescent, therapeutics, dermatitis, atopic | Phase 3 | Active not recruiting | 2024 |
| A Phase 3 Multicenter Open Label Study to Evaluate the Long term Safety Tolerability and Efficacy of TAK 279 in Subjects with Moderate to Severe Plaque Psoriasis 2024-512496-12-00 — safety, therapeutics, psoriasis | Phase 3 | Active not recruiting | 2025 |
LeadR Networks
Main global connection map